Objectives. To study the acute short-term effects on the biochemical parameters of calcium and bone homeostasis in post-menopausal women treated with a high dose of prednisone alone or with additional etidronate, before and during 5 days of treatment.
Osteoporosis and pathological fractures due to use of becomes clear that with the use of glucocorticosteroids prednisone, in a daily dosage of more than 7.5 mg for for shorter or longer time periods [13] , an uncoupling periods longer than 6 months have been recognized for between bone resorption and formation occurs. Chronic a long time [1] [2] [3] . However, the contribution of different use of glucocorticosteroids increases resorption and pathophysiological mechanisms is still unclear.
decreases formation, which leads to the development of Supraphysiological doses of glucocorticosteroids given osteopenia and fractures [2, 3, 14] . Different treatment to animals and men, result in a negative calcium balance modalities such as hormone replacement therapy, calci- [4] [5] [6] [7] which is associated with secondary hyperparathytonin, fluor and bisphosphonates have been used to roidism contributing to further calcium and bone loss prevent or treat low bone mass due to glucocorticoster- [7] [8] [9] . Also direct effects of glucocorticosteroids on oids [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . We and others found a pronounced osteoblasts have been described [10] [11] [12] . Nowadays it increase of bone mineral density (BMD) in patients with steroid-induced osteoporosis treated with etidronate or alendronate [21] [22] [23] [24] . The results suggested an additional tion alone. No data, however, have been published glucocorticoid-induced changes in circulating bone 50-170 mg/l and ICTP 1.4-5.4 mg/l. PTH was measured using a two-sided RIA. The first step involved extraction markers. The objective of the current study was to determine the short-term effect of the bisphosphonate and concentration of plasma PTH using solid-phase anti-amino-terminal antibodies. After elution, the PTH etidronate on glucocorticoid-induced changes in biochemical parameters of calcium and bone homeostasis immunoextract was analysed using a sensitive mid-and C-region immunoassay [25] . The intra-and inter-assay in post-menopausal women with temporal arteritis treated with a high dosage of glucocorticosteroids.
CV were 8.3% and 10.2%, respectively; the sensitivity of the assay was 0.8 pmol/l (normal values 0. between means of biochemical parameters, at the end were excluded from the study. All patients gave informed of the study (day 5), was determined by an independent consent to the study. The procedures followed adhered two-sample t-test (P denoted by P*). Also analysis of to the guidelines of the Helsinki declaration for physicovariance (ANCOVA, with mean pre-treatment value cian-initiated studies.
determinations and time as covariables) was performed The study participants took their prednisone at 8.00
to compare the differences between groups at day 5 of a.m. The patients in group B received 400 mg etidronate the study. Differences were considered statistically sig-1 h before prednisone intake. Breakfast was served at nificant when P < 0.05. 9.00 a.m. The patients had a dietary calcium intake of 400-800 mg before the study and they were kept on this level during the study.
Results

Measurements
Fourteen post-menopausal women were randomized to group A and group B. Each group comprised seven Blood and urine were collected at 7.00 a.m. daily for 5 days starting 1 day before any medication was taken.
women. At baseline the two treatment groups were comparable in age and biochemical parameters. Group The following biochemical parameters were evaluated before and during the first 5 days of treatment: serum A: n = 7; mean age 72 yr, range 59-82 yr. Group B: n = 7; mean age 74 yr, range 63-82 yr. The results are calcium, phosphorus, creatinine, alkaline phosphatase activity, osteocalcin, carboxy-terminal propeptide of given in Table 1 and illustrated for osteocalcin ( Fig. 1 ), urinary excretion of calcium over 24 h ( Fig. 2 ) and the type I procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP), paratelopeptide ICTP (Fig. 3) . In both groups of prednisone alone and combined prednisone and etidronate treatthyroid hormone (PTH ) and 25-hydroxyvitamin D. Urinary excretion of calcium over 24 h was measured ment, serum calcium and phosphate levels, alkaline phosphatase, PTH and 25-hydroxyvitamin D levels virdaily from day −1 to day 5. The serum and urine calcium, serum phosphorus, alkaline phosphatase and tually remained unchanged. In the prednisone alone group, serum osteocalcin creatinine were measured by autoanalyser techniques. The samples for hormonal measurements were immedilevels significantly decreased from 2.7 ± 0.3 mg/l at baseline to 1.7 ± 0.1 mg/l after 5 days (−38.1%, ately frozen and stored at −20°C until use. All hormonal measurements were performed in a one assay session. P < 0.01). In contrast, with the combined treatment group, serum osteocalcin levels steadily increased from The radioimmunoassay (RIA) used for osteocalcin measurements was the commercially available kit of 2.4 ± 0.3 mg/l at baseline to 3.0 ± 0.4 mg/l after 5 days (+27.4%, P < 0.01). The change in osteocalcin between Incstar Corporation [Stillwater, MN, USA; intra-and inter-assay coefficient of variation (CV ) 3.8% and 4.3%, the two groups was statistically significant from day 3 (P* < 0.05). The procollagen I levels remained respectively; sensitivity of the assay 0.5 mg/l; normal values 1.8-6.6 mg/l ]. PICP and ICTP results were unchanged in both treatment groups. The bone resorption marker ICTP remained virtually obtained with the RIA produced by Farmos Diagnostica (Orion Corporation Farmos, Turku, Finland). The unchanged during prednisone treatment alone, but gradually decreased in the bisphosphonate group to intra-and inter-assay CV were 4.7% and 5.3% for PICP and 6.2% and 7.9% for ICTP. Sensitivity was 1.2 mg/l levels 19.4% below baseline at day 5 (P < 0.01). At that time the difference between both groups was statistically for PICP and 0.43 mg/l for ICTP; normal values PICP, significant (P* < 0.01). Urinary calcium excretion P < 0.01). The difference in urinary calcium excretion between both groups was already statistically significant gradually increased over 5 days in the prednisone alone group (+14.7%, P < 0.05) but decreased in the comfrom day 3 on. Every patient completed the study and the study drug was well tolerated. bined prednisone and etidronate group (−22.1%, The increase in osteocalcin levels during short-term Discussion etidronate administration in glucocorticoid-treated Short-term high-dose glucocorticoid therapy in postpatients is, however, remarkable, although we must be menopausal women with fluoride arteritis temporalis careful when extrapolating our short-term study results resulted in acute changes in bone formation and resorpto the long-term benefits. tion as reflected by a 38% decrease of osteocalcin-not There are five possible mechanisms by which this PICP or alkaline phosphatase-and a 15% increase in increase in osteocalcin could be explained: first, urinary calcium excretion. The glucocorticoid-induced decreased elimination of osteocalcin by the kidney changes in bone remodelling markers have been attribduring etidronate therapy. This is unlikely since in most uted to a decrease in differentiated function of mature studies on post-menopausal osteoporosis etidronate osteoblasts leading to a decrease in osteocalcin transcripinduces a decrease in osteocalcin. Second, altered tion and-not in this study-a decrease in type I collagen degradation, third, increased production of osteocalcin, expression and increase in its degradation [10-12, 26, fourth, an indirect effect of etidronate on bone turnover 27]. Other studies administering 10-20 mg of prednisone by influencing the inflammatory process [32] and, fifth, daily for 1 week to healthy men found a similar decrease initial displacement of osteocalcin from hydroxyapatite in osteocalcin (−35%) and increase in urinary calcium by EHDP as shown by Price et al. in rats [33] . This (+45%), however, they reported a decrease in PICP [28, could also explain the initial rise in osteocalcin found 29] and both decreased [28] and increased [29] ICTP by Tobias et al. in the first 2 weeks of treatment of posthas been reported. This could be explained by the menopausal women with hormone replacement therapy different dosages of prednisone and/or the difference in or a bisphosphonate [34] . study population. Similar results were obtained in A direct or indirect stimulatory effect of bisphosphonpatients with rheumatoid arthritis given a high dose of ates on the osteoblast could be postulated, especially in dexamethasone [13] , in patients with multiple sclerosis high turnover bone disease as in patients with Paget's given huge intravenous doses of methyl prednisolone disease, in whom an increase in osteocalcin occurs after [30] and after high-dose corticosteroid inhalation [31] .
APD treatment [35] . Also, in vitamin D-deficient postFrom the present study it appears that combined menopausal osteoporotic women, chronic etidronate etidronate and glucocorticoid administration acutely therapy has been reported to induce a rise in osteocalcin reversed glucocorticoid-induced suppression of bone [36 ] . Bisphosphonates may exert their effects on the formation as reflected by a 27% increase in osteocalcin osteoblast indirectly by at least two different mechanwithin 5 days. Urinary calcium excretion decreased from isms. One is the modulation in the release of cytokines +14.7% in the prednisone alone group to −22.1% in by the osteoclast and the release of local signals due to the combined therapy group, indicating attenuation of the effects on the osteoclast function, resulting in bone resorption. This was also illustrated by a decrease decreased resorption [37] . The other is through stimulain ICTP. This decrease of bone resorption markers is tion of the production of the calciotropic hormones well known in chronically bisphosphonate-treated 1,25-dihydroxyvitamin D and PTH, which could patients on glucocorticoids, but has never been reported increase during bisphosphonate treatment [6, 38, 39] . Recently Staal et al. [40] and Zhang et al. [41] reported after such a short time interval as in this study. ids [42] . Our hypothesis is that etidronate could reverse turnover.
1158-61.
In conclusion, the present study is the first demon- 
